Details of the Drug

General Information of Drug (ID: DM3HN3U)

Drug Name

Afimetoran

Synonyms

Afimetoran; 2171019-55-7; Afimetoran [USAN]; LXP7MZL0VF; BMS-986256; UNII-LXP7MZL0VF; WHO 11516; BMS 986256; 2-(4-(2-(7,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)acetamide; 1-Piperidineacetamide, 4-(2-(7,8-dimethyl(1,2,4)triazolo(1,5-a)pyridin-6-yl)-3- (1-methylethyl)-1H-indol-5-yl)-; 2-(4-(2-(7,8-dimethyl(1,2,4)triazolo(1,5-a)pyridin-6-yl)-3-(propan-2-yl)-1H-indol-5-yl)piperidin-1-yl)acetamide; AFIMETORAN [INN]; CHEMBL4650329; SCHEMBL19761011; BDBM273241; EX-A6745; US10071079, Example 15; AKOS040757385; MS-28017; HY-139567; CS-0213544; 1-PIPERIDINEACETAMIDE, 4-(2-(7,8-DIMETHYL(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-3-(1-METHYLETHYL)-1H-INDOL-5-YL)-; 2-(4-(2-(7,8-DIMETHYL(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-3-(PROPAN-2-YL)-1H-INDOL- 5-YL)PIPERIDIN-1-YL)ACETAMIDE; 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl) piperidin-1-yl)acetamide; 2-[4-[2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-propan-2-yl-1H-indol-5-yl]piperidin-1-yl]acetamide

Indication

Disease Entry	ICD 11	Status	REF
Systemic lupus erythematosus	4A40.0	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C26H32N6O
Canonical SMILES: CC1=C(C2=NC=NN2C=C1C3=C(C4=C(N3)C=CC(=C4)C5CCN(CC5)CC(=O)N)C(C)C)C
InChI: InChI=1S/C26H32N6O/c1-15(2)24-20-11-19(18-7-9-31(10-8-18)13-23(27)33)5-6-22(20)30-25(24)21-12-32-26(28-14-29-32)17(4)16(21)3/h5-6,11-12,14-15,18,30H,7-10,13H2,1-4H3,(H2,27,33)
InChIKey: SNFVHLQYHFQOEP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 132271862
TTD ID: DW0ZV1

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Inhibitor	[2]
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Systemic lupus erythematosus

ICD Disease Classification

4A40.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Toll-like receptor 7 (TLR7)	DTT	TLR7	3.32E-25	0.44	0.88

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04895696) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight